Patients with obstructive sleep apnea in Germany

被引:0
作者
Winter, Yaroslav [1 ,2 ,9 ]
Mayer, Geert [2 ,3 ]
Benes, Heike [4 ]
Burghaus, Lothar [5 ]
Floam, Samantha [6 ]
Parks, Gregory S. [6 ]
Kallweit, Ulf [7 ,8 ]
机构
[1] Univ Saarland, Dept Neurol, Homburg, Germany
[2] Philipps Univ Marburg, Dept Neurol, Marburg, Germany
[3] Hephata Klin, Schwalmstadt, Germany
[4] Schwerin GmbH, Somni Bene GmbH Inst Med Forsch & Schlafmed, Schwerin, Germany
[5] Heilig Geist Hosp, Dept Neurol, Cologne, Germany
[6] Axsome Therapeut, New York, NY USA
[7] Univ Witten Herdecke, Ctr Biomed Educ & Res, Dept Med, Witten, Germany
[8] Univ Witten Herdecke, Dept Med, Narcolepsy & Hypersomnolence Res, Witten, Germany
[9] Univ Saarland, Dept Neurol, Kirrberger Str, D-66421 Homburg, Germany
关键词
Obstructive sleep apnea; Excessive daytime sleepiness; Europe; Germany; Solriamfetol; Real-world evidence; EXCESSIVE SLEEPINESS; DAYTIME SLEEPINESS; MECHANISMS;
D O I
10.1007/s11325-025-03275-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Solriamfetol is approved for use in the European Union to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA). SURWEY characterized real-world evidence regarding physician initiation and titration strategies and patient experiences with solriamfetol. We report SURWEY data for patients with OSA and EDS in Germany (N = 83). Methods SURWEY was a retrospective chart review conducted among physicians in Germany. Eligible patients were age >= 18 years who reached a stable solriamfetol dose and completed >= 6 weeks of treatment. Patients were grouped by solriamfetol initiation strategy: changeover, add-on, new-to-therapy. Results Patients' mean (SD) age was 49 (14) years. New-to-therapy was the most common initiation strategy. Solriamfetol was initiated at 37.5 mg/day in most patients (n = 57, 69%) and titrated in 53 patients (64%); 30 (57%) completed titration within 2 weeks. In a post-hoc analysis, mean (SD) Epworth Sleepiness Scale (ESS) score was 16.0 (3.2) at baseline and decreased by 5.4 (3.6) at final follow-up (similar to 16 weeks; p <.001). Improvement in patient- and physician-rated EDS was reported by similar to 90% of patients. Most patients (55%) reported effects of solriamfetol lasting >= 8 h; 91% of patients reported no change in nighttime sleep quality. The most frequent adverse events were headache (8%), decreased appetite (7%), and insomnia (6%). Conclusion Most patients in this study were new to therapy. Solriamfetol was typically initiated at 37.5 mg/day; titration was common. ESS scores improved with solriamfetol treatment, and most patients self-reported improvement in EDS symptoms. Common adverse events were consistent with those reported in previous clinical trials.
引用
收藏
页数:9
相关论文
共 20 条
[1]   Trace amine-associated receptor 1 (TAAR1): Potential application in mood disorders: A systematic review [J].
Alnefeesi, Yazen ;
Tamura, Jocelyn K. ;
Lui, Leanna M. W. ;
Jawad, Muhammad Youshay ;
Ceban, Felicia ;
Ling, Susan ;
Nasri, Flora ;
Rosenblat, Joshua D. ;
McIntyre, Roger S. .
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS, 2021, 131 :192-210
[2]  
[Anonymous], 2022, Sunosi (solriamfetol) tablets Prescribing Information
[3]  
[Anonymous], 2023, Sunosi (solriamfetol) tablets Summary of Product Characteristics
[4]  
[Anonymous], 2024, ClinicalTrials.gov
[5]   Characterization of the Neurochemical and Behavioral Effects of Solriamfetol (JZP-110), a Selective Dopamine and Norepinephrine Reuptake Inhibitor [J].
Baladi, Michelle G. ;
Forster, Michael J. ;
Gatch, Michael B. ;
Mailman, Richard B. ;
Hyman, Danielle L. ;
Carter, Lawrence P. ;
Janowsky, Aaron .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2018, 366 (02) :367-376
[6]   Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea Database [J].
Bonsignore, Maria R. ;
Pepin, Jean L. ;
Cibella, Fabio ;
Barbera, Calogero D. ;
Marrone, Oreste ;
Verbraecken, Johan ;
Saaresranta, Tarja ;
Basoglu, Ozen K. ;
Trakada, Georgia ;
Bouloukaki, Izolde ;
McNicholas, Walter T. ;
Bailly, Sebastien ;
Pataka, Athanasia ;
Kvamme, John A. ;
Hein, Holger ;
Mihaicuta, Stefan ;
Grote, Ludger ;
Fanfulla, Francesco .
FRONTIERS IN NEUROLOGY, 2021, 12
[7]   Risk of Occupational Accidents in Workers with Obstructive Sleep Apnea: Systematic Review and Meta-analysis [J].
Garbarino, Sergio ;
Guglielmi, Ottavia ;
Sanna, Antonio ;
Mancardi, Gian Luigi ;
Magnavita, Nicola .
SLEEP, 2016, 39 (06) :1211-1218
[8]   Residual sleepiness in sleep apnea patients treated by continuous positive airway pressure [J].
Gasa, Merce ;
Tamisier, Renaud ;
Launois, Sandrine H. ;
Sapene, Marc ;
Martin, Francis ;
Stach, Bruno ;
Grillet, Yves ;
Levy, Patrick ;
Pepin, Jean-Louis .
JOURNAL OF SLEEP RESEARCH, 2013, 22 (04) :389-397
[9]  
Gursahani H, 2022, SLEEP, V45, pA329
[10]   A NEW METHOD FOR MEASURING DAYTIME SLEEPINESS - THE EPWORTH SLEEPINESS SCALE [J].
JOHNS, MW .
SLEEP, 1991, 14 (06) :540-545